| Objective: Thyroid carcinoma is the most common endocrine-related malignancy worldwide.During the past decades,the incidence has been increasing rapidly worldwide.For the lack of specific Bio-markers,PTC's diagnosis,assessment and recurrence monitoring are facing challenges.miRNA is a small,noncoding RNA,which is expressed by a post transcriptional horizontal to negative regulating gene.Dysregulation of microRNAs(miRNAs)is well known to be involved in the development of various cancers,including PTC.This study was to investigate the expression and clinical significance of miR-1301-3p in thyroid papillary carcinoma,and inclosed the role of miR-1301-3p in the pathogenesis of PTC.Discuss the possible of miR-1301-3p as a bio-marker for PTC diagnosis,pre-operative risk assessment,treatment and recurrence monitoring.Methods: The thyroid tumor tissue and normal thyroid tissue around the tumor were collected from 65 patients with thyroid surgery at the Affiliated Hospital of Southwest Medical University from August 2015 to January 2017,in which 35 cases were benign and 30 cases were papillary carcinoma by pathology reports.Besides,We collected 22 serum samples of patients with papillary thyroid carcinoma,including 12 preoperative and 10 postoperative.The abnormal expression miR-1301-3p in PTC patients was selected from TCGA.qRT-PCR was performed to determine the expression profiles of miR-1301-3p in benign tumor tissues,PTC tissues and noncancerous tissues.And then analysis the correlations between the expression Level of miR-1301-3p and the clinicopathologic parameters in papillary thyroid cancers.ROC curve was used to value the diagnostic efficacy of miR-1301-3p.The expression of miR-1301-3p in the serum of patient's pre-and post-surgery was detected by qRT-PCR,and to discuss the potential of miR-1301-3p acting as a follow-up recurrence bio-marker for PTC.In vitro,cell viability was detected by CCK8 assay in TPC-1,apoptosis and cell cycle were detected by flow cytometry,the expression of PCNA,LC-3 and BAX were detected by Western blotting,and cell migration was detected by transwell assay.Targetscan used to predicting the mi R-1301-3p target genes and GEPIA used to analysis the miR-1301-3p target gene CLDN1 and TRPC5 expression in thyroid cancer from TCGA and GTEx database,to explore the role of mi R-1301-3p in the development of PTC.Results: The expression profile of mi R-1301-3p was down-regulated in the papillary thyroid carcinoma tissues(P<0.01).Compared with benign tumor tissues,miR-1301-3p expression was down-regulated in PTC tissues(P<0.05).Clinicopathologic parameters analysis found miR-1301-3p expression levels associated with PTC's “T” and “N” stages,the lower expression of miR-1301-3p,the higher stage.ROC curve indicated miR-1301 act as a potential diagnostic marker for PTC,the AUC was 0.774 with sensitivity of 50% and specificity of 90%.The expression of miR-1301-3p in serum of post-operation was significantly higher than pre-operation(P<0.05).In vitro,the expression level of mi R-1301-3p was lower in TPC-1 compare to Nthy-ori 3-1.Overexpression of miR-1301-3p could signifcantly inhibited the cell growth of TPC-1 and reduce the expression of proliferating cell nuclear antigen PCNA and arresting TPC-1 cell cycle in G1 phase.In addition,higher expression of miR-1301-3p could significantly inhibit the migration of TPC-1.With bioinformatics analysis,we speculated that miR-1301-3p may participate in PTC growth and migration by targeting CLDN1 and TRPC5.Conclusion: we revealed that miR-1301-3p was down-regulated in the PTC tissues and correlation with Clinicopathologic parameters,it elevated in the serum after operation.What's more,miR-1301-3p could suppress the TPC-1 growth and migration,which may by targeting CLDN1 and TRPC5.In summary,mi R-1301-3p may be a potential biological molecular marker for PTC diagnosis,pre-operative risk assessment,therapy,and surveillance. |
PDF Full Text Request